Statistics about Health, Pharma & Medtech in Sweden
Statistics
- Orexo net cash 2021-2025
- Orexo total equity 2021-2025
- Orexo gross profit 2021-2025
- Orexo revenue 2021-2025
- Orexo operating profit 2021-2025
- Oncopeptides net income 2021-2025
- Oncopeptides liabilities 2021-2025
- Oncopeptides total assets 2021-2025
- Oncopeptides total equity 2021-2025
- Oncopeptides gross profit 2021-2025
- Oncopeptides revenue 2021-2025
- Oncopeptides net cash 2021-2025
- Oncopeptides operating profit 2021-2025
- Moberg Pharma liabilities 2021-2025
- Moberg Pharma net cash 2021-2025
- Moberg Pharma total assets 2021-2025
- Moberg Pharma net income 2021-2025
- Moberg Pharma gross profit 2021-2025
- Moberg Pharma revenue 2021-2025
- Moberg Pharma total equity 2021-2025
- Moberg Pharma operating profit 2021-2025
- Mendus liabilities 2021-2025
- Mendus total assets 2021-2025
- Mendus net income 2021-2025
- Mendus net cash 2021-2025
- Mendus total equity 2021-2025
- Mendus operating profit 2021-2025
- Medivir AB net income 2021-2025
- Medivir AB total assets 2021-2025
- Medivir AB liabilities 2021-2025
- Medivir AB net cash 2021-2025
- Medivir AB total equity 2021-2025
- Medivir AB revenue 2021-2025
- Medicover liabilities 2021-2025
- Medivir AB operating profit 2021-2025
- Medicover net income 2021-2025
- Medicover total assets 2021-2025
- Medicover total equity 2021-2025
- Medicover net cash 2021-2025
- Medicover revenue 2021-2025
- Medicover gross profit 2021-2025
- Medicover operating profit 2021-2025
- MedCap total assets 2021-2025
- MedCap net income 2021-2025
- MedCap net cash 2021-2025
- MedCap liabilities 2021-2025
- MedCap gross profit 2021-2025
- MedCap revenue 2021-2025
- MedCap total equity 2021-2025
- MedCap operating profit 2021-2025
- Karolinska Development total assets 2021-2025
- Karolinska Development net income 2021-2025
- Karolinska Development liabilities 2021-2025
- Karolinska Development revenue 2021-2025
- Karolinska Development total equity 2021-2025
- Karolinska Development operating profit 2021-2025
- Karolinska Development net cash 2021-2025
- Infant Bacterial TherapeuticsB net income 2021-2025
- Infant Bacterial TherapeuticsB liabilities 2021-2025
- Infant Bacterial TherapeuticsB total equity 2021-2025
- Infant Bacterial TherapeuticsB total assets 2021-2025
- Infant Bacterial TherapeuticsB net cash 2021-2025
- Infant Bacterial TherapeuticsB operating profit 2021-2025
- Immunovia liabilities 2021-2025
- Immunovia net cash 2021-2025
- Immunovia total assets 2021-2025
- Immunovia net income 2021-2025
- Immunovia gross profit 2021-2025
- Immunovia total equity 2021-2025
- Immunovia revenue 2021-2025
- Immunovia operating profit 2021-2025
- IRLAB Therapeutics net income 2021-2025
- IRLAB Therapeutics liabilities 2021-2025
- IRLAB Therapeutics net cash 2021-2025
- IRLAB Therapeutics total equity 2021-2025
- IRLAB Therapeutics total assets 2021-2025
- IRLAB Therapeutics revenue 2021-2025
- IRLAB Therapeutics operating profit 2021-2025
- Humana AB liabilities 2021-2025
- Humana AB net cash 2021-2025
- Humana AB net income 2021-2025
- Humana AB total assets 2021-2025
- Humana AB total equity 2021-2025
- Humana AB operating profit 2021-2025
- Humana AB revenue 2021-2025
- Hansa Biopharma total assets 2021-2025
- Hansa Biopharma liabilities 2021-2025
- Hansa Biopharma net income 2021-2025
- Hansa Biopharma total equity 2021-2025
- Hansa Biopharma revenue 2021-2025
- Hansa Biopharma net cash 2021-2025
- Hansa Biopharma gross profit 2021-2025
- Hansa Biopharma operating profit 2021-2025
- Getinge liabilities 2021-2025
- Getinge net income 2021-2025
- Getinge net cash 2021-2025
- Getinge total assets 2021-2025
- Getinge gross profit 2021-2025
- Getinge revenue 2021-2025
- Getinge total equity 2021-2025